FRANCES BENNETT: Open Payments
NPI 1871725622 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,655 in 119 payments from 16 companies in 2025. Trend: 2023 $759 · 2024 $1,357 · 2025 $2,655
Food & beverage: $2,650Education: $5
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $401 |
| Vanda Pharmaceuticals Inc. | 14 | $401 |
| Alkermes, Inc. | 19 | $294 |
| Teva Pharmaceuticals USA, Inc. | 9 | $281 |
| Janssen Pharmaceuticals, Inc | 8 | $242 |
| ABBVIE INC. | 14 | $232 |
| Otsuka America Pharmaceutical, Inc. | 8 | $182 |
| E.R. Squibb & Sons, L.L.C. | 10 | $147 |
| Collegium Pharmaceutical, Inc. | 7 | $123 |
| Lundbeck LLC | 3 | $82 |
Products named: CAPLYTA, FANAPT, ARISTADA, AUSTEDO XR, VRAYLAR, REXULTI, COBENFY, INVEGA SUSTENNA.
Industry payments across LA — which companies pay providers there.
